# ARVs to Prevent Breastmilk HIV:Viral and Immune Responses

> **NCT00167674** · PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 58 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Combined short-course zidovudine/nevirapine
- **DRUG:** HAART

## Key facts

- **NCT ID:** NCT00167674
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11-03
- **Primary completion:** 2005-03
- **Final completion:** 2006-04
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00167674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00167674, "ARVs to Prevent Breastmilk HIV:Viral and Immune Responses". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00167674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*